SCHEMBL25660337

SCHEMBL25660337

NC(C(=O)O)[C@H]1CCOC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 3/20 0.39
SLC1A1 P43005 2/20 0.39
CYP2C19 P33261 2/20 0.36
GRM2 Q14416 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP2C9 P11712 1/20 0.36
GRM8 O00222 1/20 0.36
GRM6 O15303 1/20 0.36
LMNA P02545 1/20 0.36
APEX1 P27695 1/20 0.36
GRM5 P41594 1/20 0.36
PMP22 Q01453 1/20 0.36
GRM1 Q13255 1/20 0.36
GRM3 Q14832 1/20 0.36
GRM4 Q14833 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8270998 1.00 SLC1A2 (0.39) SLC1A2SLC1A1CYP2C19GRM2MEN1
SCHEMBL25660516 1.00 SLC1A2 (0.39) SLC1A2SLC1A1CYP2C19GRM2MEN1
SCHEMBL14693847 1.00 SLC1A2 (0.39) SLC1A2SLC1A1CYP2C19GRM2MEN1
SCHEMBL16977455 1.00 SLC1A2 (0.39) SLC1A2SLC1A1CYP2C19GRM2MEN1
Hydrochloric Acid SCHEMBL16968617 0.98 SLC1A2 (0.38) SLC1A2SLC1A1CYP2C19GRM2MEN1
SCHEMBL25660416 0.88 SLC1A2 (0.37) SLC1A2SLC1A1CYP2C19GRM2MEN1
SCHEMBL1770232 0.87 SLC1A2 (0.42) SLC1A2SLC1A1CYP2C19GRM2MEN1
SCHEMBL205456 0.87 SLC1A2 (0.42) SLC1A2SLC1A1CYP2C19GRM2MEN1
SCHEMBL1531563 0.82
SCHEMBL21994628 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 US disclosed
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF PAICS, LNPEP, DNPEP SLC1A2 236/4885SLC1A1 142/4885CYP2C19 3486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.